Publications

1. GVS advice dapagliflozin (Forxiga®) extension of further condition

   The National Health Care Institute has completed its assessment whether the further condition of dapagliflozin (Forxiga®) could ...

   Report | 12-05-2021

2. Package advice pertuzumab and trastuzumab (Phesgo®) for the treatment of breast cancer

   Zorginstituut Nederland has completed its assessment whether the fixed combined dose of pertuzumab and trastuzumab (Phesgo®) can ...

   Report | 11-05-2021

3. Package advice onasemnogene abeparvovec (Zolgensma®) for the treatment of SMA

   Zorginstituut Nederland has completed its assessment whether onasemnogene abeparvovec (Zolgensma®) for the treatment of patients ...

   Report | 06-05-2021

4. GVS advice inclisiran (Leqvio®) for the treatment of hypercholesterolemia

   The National Health Care Institute has completed its assessment whether inclisiran (Leqvio®) is interchangeable with a product ...

   Report | 04-05-2021

5. Advice on the clustering of combination products and ghost clusters in GVS (part 1)

   The Minister of Medical Care has asked Zorginstituut Nederland questions about the clustering of two categories of medicinal ...

   Report | 04-05-2021

6. GVS advice elexacaftor/tezacaftor/ivacaftor (Kaftrio®) in combination with ivacaftor (Kalydeco®)

   The National Health Care Institute has completed its assessment whether elexacaftor/tezacaftor/ivacaftor (Kaftrio®) in ...

   Report | 29-04-2021

7. GVS assessment of trientine dihydrochloride (Cufence®) for the treatment of Wilson’s disease

   The National Health Care Institute has completed its assessment whether trientine dihydrochloride (Cufence®) can be included in ...

   Report | 19-04-2021

8. GVS assessment of crisaborole (Staquis®) for the treatment of atopic dermatitis

   The National Health Care Institute has completed its assessment whether crisaborole (Staquis®) is interchangeable with a product ...

   Report | 15-04-2021

9. GVS assessment of rivaroxaban (Xarelto®) for the treatment of VTE and prevention of VTE recurrence in children

   The National Health Care Institute has completed its assessment whether rivaroxaban (Xarelto®) 1 mg/ml suspension can be included ...

   Report | 17-03-2021

10. Advice on a potential candidate for conditional inclusion of entrectinib (Rozlytrek®) for solid tumours with NTRK gene fusion

    Zorginstituut Nederland recommends that entrectinib should be designated as a potential candidate for conditional inclusion. ...

    Letter | 10-03-2021